BIM.PA AI Price Prediction

With a PE ratio of 21.32 and EPS of 3.36, bioMérieux S.A. appears reasonably valued for a profitable, established diagnostics company, but not obviously cheap. The valuation suggests the market expects steady, not explosive, earnings growth. Without explicit recent revenue and margin data, the picture is one of solid but unspectacular financial strength.

• A PE of 21.32 implies the market is pricing in moderate growth and relatively stable earnings rather than deep value or high‑growth characteristics.
• EPS of 3.36 confirms the company is clearly profitable and generating meaningful earnings per share.
• In the absence of detailed revenue and margin trends, the valuation multiples suggest a mature, cash‑generative business with balanced risk/reward rather than a strongly mispriced opportunity.

Overall, the picture for bioMérieux S.A. is neutral: operational and alternative data indicators lean constructive, but the stock’s technical profile remains weak with the price far below its 200‑day moving average. The valuation and earnings profile suggest a solid, profitable company, yet the market is still discounting the shares relative to their recent historical trend.

• Fundamentals and alternative data (hiring growth, stable web and social presence) are supportive and tilt slightly positive for the medium term.
• However, the pronounced technical downtrend and price discount to the 200‑day moving average argue for caution until clearer signs of a sustained recovery emerge.